

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

FI SEVIER

Contents lists available at ScienceDirect

American Journal of Emergency Medicine

journal homepage: www.elsevier.com/locate/ajem



Case Report

Acute myocarditis associated with COVID-19 infection☆

Muhammed Said Beşler, M.D.*, Halil Arslan, M.D., Prof.

Department of Radiology, Ankara City Hospital, Ankara, Turkey



ARTICLE INFO

Article history: Received 4 May 2020 Received in revised form 20 May 2020 Accepted 25 May 2020

Keywords: COVID-19 Myocarditis

ABSTRACT

We present the case of a 20-year-old male patient without previous history of cardiovascular disease who was admitted to our hospital with a new onset febrile sensation and chest pain. Chest computed tomography revealed a subpleural consolidation with a halo of ground-glass opacification. Blood tests revealed elevated levels of markers of myocyte necrosis (troponin I and creatine kinase–MB). Nasopharyngeal swab was positive for COVID-19. Cardiac MRI showed myocardial edema and late gadolinium enhancement compatible with myocarditis associated with COVID-19 infection. This case showed that acute myocarditis can be the initial presentation of patients with COVID-19 infection.

© 2020 Elsevier Inc. All rights reserved.

1. Introduction

Coronavirus disease 2019 (COVID-19) has been declared a world-wide public health emergency. There is limited published data concerning cardiovascular presentations in the wake of viral epidemics [1]. Acute or fulminant myocarditis as well as heart failure have been reported with Middle East respiratory syndrome coronavirus and could be expected to occur with SARS-CoV-2, given the similar pathogenicity [2]. Previous severe acute respiratory syndrome (SARS) beta-coronavirus infections could be associated with tachyarrhythmias and signs and symptoms of heart failure [3]. The current report describes a case of myocarditis in a patient affected by COVID-19.

2. Case report

A 20-year-old male patient without previous history of cardiovascular disease admitted to our hospital with a new onset febrile sensation and chest pain during the COVID-19 outbreak. On arrival to the emergency department, physical examination revealed blood pressure of 146/63 mmHg, heart rate of 111 beats per minute, oxygen saturation of 97%, and body temperature of 39 °C. The posteroanterior chest radiograph revealed a focal consolidation on the upper zone of left lung (Fig. 1A). A chest computed tomography (CT) revealed a subpleural consolidation containing air bronchogram with a halo of ground-glass opacification in the left upper lobe (Fig. 1B). Troponin I level was 0.572 ng/mL (<0.045 ng/mL), creatine kinase–MB level was 9.08 μg/L (<5 μg/L), N-terminal pro-B-type natriuretic peptide (NT-proBNP)

E-mail address: msbesler@gmail.com (M.S. Beşler).

level was 127 ng/L (<125 ng/L), and C-reactive protein level was 0.0812 g/L (0.005 g/L). Blood cell counts show a haemoglobin concentration of 15.3 g/dL, a platelet count of 203×10^9 per L, and a leucocyte count of 6.74×10^9 per L (neutrophils 71%, lymphocytes 21%, monocytes 8%, and no eosinophils or basophils 0%). Nasopharyngeal swab was positive for COVID-19. Hydroxychloroquine, azithromycin, ceftriaxone, tigecycline, favipiravir, and colchicine were started. On the first day after hospital admission, there was a further increase in levels of Troponin I (7.621 ng/mL), creatine kinase-MB (21.92 µg/L), and NT-proBNP (1525 ng/L), with a gradually reduction to normal range during the following days. The patient was recovered and was discharged to home on day 7. One week later, a cardiac magnetic resonance imaging (MRI) was performed. Left ventricular function, volumes, and mass were in normal range (ejection fraction 64%, stroke volume 62.2 mL, end-diastolic volume 97 mL, end-systolic volume 34.8 mL, mass 128 g) (Video 1). T2 short tau inversion recovery (STIR) sequence revealed a subepicardial high signal intensity in the mid posterolateral wall of the left ventricle which suggests myocardial wall edema (Fig. 2A). Cardiac MRI showed subepicardial late gadolinium enhancement of the posterolateral wall in the mid ventricle-suggestive of myocarditis at 5 and 10 min after contrast administration, respectively (Fig. 2B, C). The myocardial edema and pattern of late gadolinium enhancement were compatible with the Lake Louise criterias for the diagnosis of acute myocarditis [4]. Myocarditis combined with COVID-19 was confirmed by clinical presentation, elevated levels of markers of myocyte necrosis, and cardiac MRI.

3. Discussion

Herein, we present a patient without a known history of cardiovascular disease admitted to the hospital with COVID-19 pneumonia and acute myocarditis. The current case presentation shows that cardiac involvement may occur with COVID-19 pneumonia. Although the clinical

[☆] There is no conflict of interest.

^{*} Corresponding author at: Ankara City Hospital, Bilkent Street No: 1 Çankaya, Ankara, Turkev.




Fig. 1. Note that an opacity (arrow) in left lung at posteroanterior chest radiograph (A). Chest computed tomography (CT) reveals a consolidation containing air bronchogram with a halo sign in the left upper lobe and a subpleural localization (B).



Fig. 2. Short tau inversion recovery (STIR) sequence in short-axis view (A) reveals a subepicardial high signal intensity in the posterolateral wall of the left ventricle which suggests myocardial wall edema (arrow). Phase-sensitive inversion recovery (PSIR) sequence in short-axis view shows subepicardial late gadolinium enhancement of the posterolateral wall in the mid ventricle at 5 (B) and 10 (C) minutes after contrast administration (arrowheads).

manifestations of COVID-19 are dominated by respiratory symptoms, some patients have severe cardiovascular damage [5]. Virus infection has been widely described as one of the most common infectious causes of myocarditis [6,7]. As with other coronaviruses, SARS-CoV-2 can elicit the release of multiple cytokines and chemokines that can lead to myocardial inflammation. Direct viral infection of the myocardium is another possible causal pathway of myocardial damage. In some patients with or without preexisting cardiovascular disease, COVID-19 associated myocardial injury could represent myocarditis [2]. However, less is known about the cardiac involvement as a complication of SARS-CoV-2 infection. Suspected myocarditis is one of the most frequent indications for cardiac MRI scanning [8,9]. Cardiac MRI allows for targeting several features of myocarditis inflammatory hyperemia and edema, necrosis/scar, and contractile dysfunction can all be visualized [8]. There were a few cases described myocarditis with COVID-19. Cardiac MRIs of these cases showed diffuse myocardial wall edema and decreased LV ejection fraction [6,10]. However, cardiac MRI of this patient revealed focal myocardial wall edema with normal left ventricular function and volumes. In our patient, increases of markers of myocyte necrosis, the cardiac MRI findings showing focal edema, and the late gadolinium enhancement are compatible with an acute myocarditis.

In conclusion, it should be kept in mind that COVID-19 associated myocardial injury could represent myocarditis. This is one of the first reported cases of myocarditis associated with COVID-19 infection.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ajem.2020.05.100.

References

- [1] Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020. https://doi.org/10. 1093/eurheartj/ehaa231 [Epub ahead of print].
- [2] Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. https://doi. org/10.1001/jamacardio.2020.1105. [Epub ahead of print].
- [3] Yu CM, Wong RS, Wu EB, Kong SL, Wong J, Yip GW, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140-4.
- [4] Friedrich MG, Sechtem U, Schulz-menger J, Alakija P, Cooper LT, White JA, et al. Cardiovascular magnetic resonance in myocarditis: a JACC White paper. J Am Coll Cardiol. 2010;53:1475–87.
- [5] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
- [6] Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1096 [Epub ahead of print].
- [7] Fung G, Luo H, Qiu Y, Yang D, McManus B. Myocarditis. Circ Res. 2016;118(3): 496-514.
- [8] Friedrich MG, Marcotte F. Cardiac magnetic resonance assessment of myocarditis. Circ Cardiovasc Imaging, 2013;6:833–9.
- [9] Bruder O, Wagner A, Lombardi M, Schwitter J, van Rossum A, Pilz G, et al. European cardiovascular magnetic resonance (EuroCMR) registry–multi national results from 57 centers in 15 countries. J Cardiovasc Magn Reson. 2013;15:9.
- [10] Kim IC, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J. 2020:ehaa288. https://doi.org/10.1093/eurheartj/ ehaa288 Apr 13. [Epub ahead of print].